RU2724345C2 - N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ - Google Patents
N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ Download PDFInfo
- Publication number
- RU2724345C2 RU2724345C2 RU2018115722A RU2018115722A RU2724345C2 RU 2724345 C2 RU2724345 C2 RU 2724345C2 RU 2018115722 A RU2018115722 A RU 2018115722A RU 2018115722 A RU2018115722 A RU 2018115722A RU 2724345 C2 RU2724345 C2 RU 2724345C2
- Authority
- RU
- Russia
- Prior art keywords
- pyrazolo
- carboxamide
- pyridin
- phenyl
- cyclobutyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562239647P | 2015-10-09 | 2015-10-09 | |
| US62/239,647 | 2015-10-09 | ||
| US201662309794P | 2016-03-17 | 2016-03-17 | |
| US62/309,794 | 2016-03-17 | ||
| PCT/IB2016/056029 WO2017060874A1 (fr) | 2015-10-09 | 2016-10-07 | Pyrazolo[3,4-b]pyridin-6-carboxamides n-sulfonylés et leur procédé d'utilisation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018115722A RU2018115722A (ru) | 2019-11-12 |
| RU2018115722A3 RU2018115722A3 (fr) | 2020-02-18 |
| RU2724345C2 true RU2724345C2 (ru) | 2020-06-23 |
Family
ID=57209654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018115722A RU2724345C2 (ru) | 2015-10-09 | 2016-10-07 | N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ |
Country Status (32)
| Country | Link |
|---|---|
| US (4) | US9890158B2 (fr) |
| EP (1) | EP3359541B1 (fr) |
| JP (1) | JP6779992B2 (fr) |
| KR (1) | KR20180083323A (fr) |
| CN (1) | CN108513574B (fr) |
| AU (1) | AU2016333856C1 (fr) |
| BR (1) | BR112018007161B1 (fr) |
| CA (1) | CA3001096A1 (fr) |
| CL (1) | CL2018000911A1 (fr) |
| CO (1) | CO2018003716A2 (fr) |
| CR (1) | CR20180215A (fr) |
| CY (1) | CY1123545T1 (fr) |
| DK (1) | DK3359541T3 (fr) |
| EC (1) | ECSP18032223A (fr) |
| ES (1) | ES2829636T3 (fr) |
| HR (1) | HRP20201618T1 (fr) |
| HU (1) | HUE051067T2 (fr) |
| IL (1) | IL258553A (fr) |
| LT (1) | LT3359541T (fr) |
| MX (1) | MX2018004359A (fr) |
| NZ (1) | NZ741223A (fr) |
| PE (1) | PE20181348A1 (fr) |
| PH (1) | PH12018500765B1 (fr) |
| PL (1) | PL3359541T3 (fr) |
| PT (1) | PT3359541T (fr) |
| RU (1) | RU2724345C2 (fr) |
| SG (1) | SG11201802932VA (fr) |
| SI (1) | SI3359541T1 (fr) |
| TW (1) | TWI720032B (fr) |
| UY (1) | UY36943A (fr) |
| WO (1) | WO2017060874A1 (fr) |
| ZA (1) | ZA201802976B (fr) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3359541T3 (pl) * | 2015-10-09 | 2021-01-11 | AbbVie Overseas S.à r.l. | N-SULFONYLOWANE PIRAZOLO[3,4-b]PIRYDYNO-6-KARBOKSAMIDY I SPOSÓB ZASTOSOWANIA |
| US10138227B2 (en) | 2016-06-03 | 2018-11-27 | Abbvie S.Á.R.L. | Heteroaryl substituted pyridines and methods of use |
| US9981910B2 (en) | 2016-10-07 | 2018-05-29 | Abbvie S.Á.R.L. | Substituted pyrrolidines and methods of use |
| US10399940B2 (en) | 2016-10-07 | 2019-09-03 | Abbvie S.Á.R.L. | Substituted pyrrolidines and methods of use |
| EP3558982A1 (fr) | 2016-12-20 | 2019-10-30 | AbbVie S.À.R.L. | Modulateurs cftr deutérés et procédés d'utilisation |
| TW201831471A (zh) | 2017-02-24 | 2018-09-01 | 盧森堡商艾伯維公司 | 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法 |
| US10988454B2 (en) * | 2017-09-14 | 2021-04-27 | Abbvie Overseas S.À.R.L. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
| WO2019193062A1 (fr) | 2018-04-03 | 2019-10-10 | Abbvie S.Á.R.L | Pyrrolidines substituées et leur utilisation |
| GB201905711D0 (en) | 2019-04-24 | 2019-06-05 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases |
| US11345691B2 (en) | 2019-06-03 | 2022-05-31 | AbbVie Global Enterprises Ltd. | Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
| EP3983388A1 (fr) * | 2019-06-12 | 2022-04-20 | Nodthera Limited | Dérivés de sulfonamide et leurs utilisations |
| TW202115014A (zh) | 2019-07-12 | 2021-04-16 | 美商奧佛麥德公司 | 用於治療囊腫纖維化之化合物 |
| CN115843272A (zh) | 2020-05-08 | 2023-03-24 | 哈利亚治疗公司 | Nek7激酶的抑制剂 |
| BR112022025012A2 (pt) | 2020-06-08 | 2023-02-14 | Halia Therapeutics Inc | Inibidores de quinase de nek7 |
| CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| AU2021329507A1 (en) | 2020-08-20 | 2023-03-09 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating respiratory diseases characterized by mucus hypersecretion |
| US20220213041A1 (en) | 2021-01-06 | 2022-07-07 | AbbVie Global Enterprises Ltd. | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use |
| US20220211692A1 (en) | 2021-01-06 | 2022-07-07 | AbbVie Global Enterprises Ltd. | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use |
| WO2023150237A1 (fr) | 2022-02-03 | 2023-08-10 | Vertex Pharmaceuticals Incorporated | Méthodes de traitement de la fibrose kystique |
| WO2023150236A1 (fr) | 2022-02-03 | 2023-08-10 | Vertex Pharmaceuticals Incorporated | Procédés de préparation et formes cristallines de (6a,12a)-17-amino-12-méthyl-6,15-bis(trifluorométhyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadéca-1(18),2,4,14,16-pentaén-6-ol |
| WO2023154291A1 (fr) | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique |
| WO2023224931A1 (fr) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Méthodes de traitement de la fibrose kystique |
| CN115806532A (zh) * | 2022-08-31 | 2023-03-17 | 大连百傲化学股份有限公司 | 一种mit中杂质的制备方法 |
| WO2024059200A1 (fr) | 2022-09-14 | 2024-03-21 | Halia Therapeutics, Inc. | Inhibiteurs de nek7 |
| CN115960100B (zh) * | 2022-12-28 | 2023-08-18 | 北京康立生医药技术开发有限公司 | 一种治疗胃肠道间质瘤药物皮咪特昔布的合成方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090197911A1 (en) * | 2004-08-20 | 2009-08-06 | Ingrid Gunda Georg | Lonidamine analogues and treatment of polycystic kidney disease |
| RU2378274C2 (ru) * | 2004-03-16 | 2010-01-10 | Глаксо Груп Лимитед | ПИРАЗОЛО[3,4-b]ПИРИДИНОВОЕ СОЕДИНЕНИЕ И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРА ФДЭ4 |
| WO2014081820A1 (fr) * | 2012-11-20 | 2014-05-30 | Discoverybiomed, Inc. | Correcteurs de cftr à petites molécules |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3833598A (en) * | 1972-12-29 | 1974-09-03 | Squibb & Sons Inc | Amino derivatives of pyrazolopyridine-6-carboxylic acids and esters |
| GB0217431D0 (en) | 2002-07-27 | 2002-09-04 | Astrazeneca Ab | Novel compounds |
| EP1765347A4 (fr) | 2004-06-04 | 2008-10-01 | Univ California | Composes intervenant dans l'acceleration du transport ionique par le cftr mutant, et utilisations desdits composes |
| ME02970B (fr) | 2004-06-24 | 2018-07-20 | Vertex Pharma | Modulateurs de transporteurs de cassette de liaison a l ́ATP |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| DE602005011286D1 (en) * | 2004-07-05 | 2009-01-08 | Astellas Pharma Inc | Pyrazolopyridinderivate |
| HUE025553T2 (en) | 2007-05-25 | 2016-02-29 | Vertex Pharma | CFTR modulators |
| US20100331297A1 (en) * | 2007-11-07 | 2010-12-30 | Foldrx Pharmaceuticals, Inc. | Modulation of protein trafficking |
| CL2008003651A1 (es) | 2007-12-10 | 2009-06-19 | Novartis Ag | Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias. |
| EP2231671B1 (fr) | 2007-12-13 | 2013-04-24 | Vertex Pharmaceuticals Incorporated | Modulateurs de régulateur de conductance transmembranaire de fibrose cystique |
| KR20110074916A (ko) | 2008-10-23 | 2011-07-04 | 버텍스 파마슈티칼스 인코포레이티드 | Ｎ-(4-(7-아자비시클로［2.2.1］헵탄-7-일)-2-(트리플루오로메틸)페닐)-4-옥소-5-(트리플루오로메틸)-1,4-디히드로퀴놀린-3-카르복스아미드의 고체 형태 |
| EP2382197B1 (fr) | 2008-12-30 | 2016-10-05 | Vertex Pharmaceuticals Incorporated | Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| US20130303761A1 (en) * | 2010-09-14 | 2013-11-14 | Instytut Biochemii I Biofizyki Pan | Compounds as modulators of a mutant cftr protein and their use for treating diseases associated with cftr protein malfunction |
| BR112013007907A2 (pt) | 2010-10-08 | 2016-06-14 | N30 Pharmaceuticals Inc | novos compostos de quinolina substituída como inibidores de s-nitrosoglutationa reductase |
| WO2013038381A1 (fr) | 2011-09-16 | 2013-03-21 | Novartis Ag | Dérivés d'amide pyridine/pyrazine |
| WO2013038390A1 (fr) | 2011-09-16 | 2013-03-21 | Novartis Ag | Hétérocyclyle carboxamides n-substitués |
| WO2013038378A1 (fr) | 2011-09-16 | 2013-03-21 | Novartis Ag | Dérivés pyridinamides |
| WO2013038373A1 (fr) | 2011-09-16 | 2013-03-21 | Novartis Ag | Dérivés pyrimidinamides |
| WO2013038386A1 (fr) | 2011-09-16 | 2013-03-21 | Novartis Ag | Composés hétérocycliques destinés au traitement de la mucosviscidose |
| ES2716723T3 (es) | 2011-09-20 | 2019-06-14 | Univ North Carolina Chapel Hill | Regulación de los canales de sodio por las proteínas PLUNC |
| RU2014121984A (ru) * | 2011-10-31 | 2015-12-10 | Ксенон Фармасьютикалз Инк. | Бензолсульфонамидные соединения и их применение в качестве терапевтических средств |
| WO2014180562A1 (fr) | 2013-05-07 | 2014-11-13 | Galapagos Nv | Nouveaux composés et leurs compositions pharmaceutiques pour le traitement de la mucoviscidose |
| SG11201600891UA (en) | 2013-08-08 | 2016-03-30 | Galapagos Nv | Thieno[2,3-c]pyrans as cftr modulators |
| CN106458985B (zh) * | 2014-02-06 | 2019-05-03 | 艾伯维公司 | 6-杂芳氧基-和6-芳氧基-喹啉-2-甲酰胺及其用途 |
| AU2015229117A1 (en) | 2014-03-13 | 2016-09-29 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing CFTR activity |
| CA2942386A1 (fr) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Composes, compositions et procedes pour augmenter l'activite du cftr |
| BR112017009194A2 (pt) | 2014-10-31 | 2017-12-26 | Abbvie Sarl | tetra-hidropiranos substituídos e método de uso |
| SG11201703391VA (en) | 2014-10-31 | 2017-05-30 | Abbvie S À R L | Substituted chromanes and method of use |
| PL3359541T3 (pl) * | 2015-10-09 | 2021-01-11 | AbbVie Overseas S.à r.l. | N-SULFONYLOWANE PIRAZOLO[3,4-b]PIRYDYNO-6-KARBOKSAMIDY I SPOSÓB ZASTOSOWANIA |
| CN108602816A (zh) * | 2015-10-09 | 2018-09-28 | 艾伯维公司 | 用于治疗囊性纤维化的新颖化合物 |
-
2016
- 2016-10-07 PL PL16788232T patent/PL3359541T3/pl unknown
- 2016-10-07 BR BR112018007161-7A patent/BR112018007161B1/pt active IP Right Grant
- 2016-10-07 TW TW105132676A patent/TWI720032B/zh active
- 2016-10-07 US US15/287,911 patent/US9890158B2/en active Active
- 2016-10-07 SI SI201630965T patent/SI3359541T1/sl unknown
- 2016-10-07 SG SG11201802932VA patent/SG11201802932VA/en unknown
- 2016-10-07 EP EP16788232.3A patent/EP3359541B1/fr active Active
- 2016-10-07 CR CR20180215A patent/CR20180215A/es unknown
- 2016-10-07 JP JP2018517444A patent/JP6779992B2/ja active Active
- 2016-10-07 DK DK16788232.3T patent/DK3359541T3/da active
- 2016-10-07 KR KR1020187012937A patent/KR20180083323A/ko not_active Application Discontinuation
- 2016-10-07 HU HUE16788232A patent/HUE051067T2/hu unknown
- 2016-10-07 RU RU2018115722A patent/RU2724345C2/ru active
- 2016-10-07 NZ NZ741223A patent/NZ741223A/en unknown
- 2016-10-07 PT PT167882323T patent/PT3359541T/pt unknown
- 2016-10-07 CN CN201680069459.4A patent/CN108513574B/zh active Active
- 2016-10-07 CA CA3001096A patent/CA3001096A1/fr active Pending
- 2016-10-07 LT LTEP16788232.3T patent/LT3359541T/lt unknown
- 2016-10-07 PE PE2018000521A patent/PE20181348A1/es unknown
- 2016-10-07 AU AU2016333856A patent/AU2016333856C1/en active Active
- 2016-10-07 ES ES16788232T patent/ES2829636T3/es active Active
- 2016-10-07 MX MX2018004359A patent/MX2018004359A/es unknown
- 2016-10-07 WO PCT/IB2016/056029 patent/WO2017060874A1/fr active Application Filing
- 2016-10-11 UY UY0001036943A patent/UY36943A/es not_active Application Discontinuation
-
2017
- 2017-12-15 US US15/843,917 patent/US10259810B2/en active Active
-
2018
- 2018-04-06 PH PH12018500765A patent/PH12018500765B1/en unknown
- 2018-04-06 CO CONC2018/0003716A patent/CO2018003716A2/es unknown
- 2018-04-08 IL IL258553A patent/IL258553A/en active IP Right Grant
- 2018-04-09 CL CL2018000911A patent/CL2018000911A1/es unknown
- 2018-04-26 EC ECIEPI201832223A patent/ECSP18032223A/es unknown
- 2018-05-07 ZA ZA2018/02976A patent/ZA201802976B/en unknown
-
2019
- 2019-03-06 US US16/293,973 patent/US20190202823A1/en not_active Abandoned
- 2019-06-18 US US16/444,495 patent/US10647717B2/en active Active
-
2020
- 2020-10-08 HR HRP20201618TT patent/HRP20201618T1/hr unknown
- 2020-11-03 CY CY20201101034T patent/CY1123545T1/el unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2378274C2 (ru) * | 2004-03-16 | 2010-01-10 | Глаксо Груп Лимитед | ПИРАЗОЛО[3,4-b]ПИРИДИНОВОЕ СОЕДИНЕНИЕ И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРА ФДЭ4 |
| US20090197911A1 (en) * | 2004-08-20 | 2009-08-06 | Ingrid Gunda Georg | Lonidamine analogues and treatment of polycystic kidney disease |
| WO2014081820A1 (fr) * | 2012-11-20 | 2014-05-30 | Discoverybiomed, Inc. | Correcteurs de cftr à petites molécules |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2724345C2 (ru) | N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ | |
| AU2021282409B2 (en) | Heteroaryl substituted pyridines and methods of use | |
| USRE47848E1 (en) | Biheteroaryl compounds and uses thereof | |
| CA2822166C (fr) | Derives d'indazolyl triazole en tant qu'inhibiteurs d'irak | |
| IL283979A (en) | Transformed benzamides 3,1 – thiazole – 2 – il | |
| CA3098348A1 (fr) | Inhibiteurs de bcl-2 | |
| AU2016333855A1 (en) | Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and their use | |
| CA3010890C (fr) | Derives de quinolin-2-one | |
| KR20150135794A (ko) | 6-(5-히드록시-1h-피라졸-1-일)니코틴아미드 유도체 및 ｐｈｄ의 저해제로서의 그의 용도 | |
| MX2014003612A (es) | Compuestos de pirazol-4-il-heterociclil-carboxamida y metodos de uso. | |
| AU2018326734B2 (en) | Substituted 2-azabicyclo(3.1.1)heptane and 2-azabicyclo(3.2.1)octane derivatives as orexin receptor antagonists | |
| TW202106685A (zh) | 抗b型肝炎病毒(hbv)之新穎苯基及吡啶基脲活性劑 | |
| TW202106687A (zh) | 抗b型肝炎病毒(hbv)之新穎吲哚-2-羧醯胺活性劑 |